Table 1

Demographic, clinical, and radiological characteristics of 34 patients assessed at 6 years of follow up

RF, rheumatoid factor; HAQ, Health Assessment Questionnaire; DAS, disease activity score; ESR, erythrocyte sedimentation rate; CRP, C reactive protein; NSAID, non-steroidal anti-inflammatory drug; DMARD, disease modifying antirheumatic drug.
Median age at diagnosis (years)48.5
IgM RF ever positive during follow up30 (88%)
Disease activity, median (range)
HAQ score0.33 (0–1.6)
Ritchie index5 (0–15)
Swollen joint count3.5 (0–21)
DAS2.7 (0.9–4.6)
ESR (mm/1st h)26 (5–129)
CRP (mg/l)7 (3–69)
Radiographic characteristics
Joint erosions on x ray (hands and feet)28 (82%)
Median total modified Sharp score27
NSAID20 (59%)
    Total21 (62%)
    Methotrexate (7.5–17.5 mg/week)14
    Sulfasalazine(1–3 g/day)9
    Hydroxychloroquine (400 mg/day)2
    Leflunomide (20 mg/day)2
    Azathioprine (100 mg/day)1
Ever DMARD use31 (91%)